<DOC>
	<DOCNO>NCT00127959</DOCNO>
	<brief_summary>This randomize multicentre trial emtricitabine ( FTC ) versus tenofovir ( TDF ) /FTC antiretroviral naive subject HIV/HBV co-infection 48 week ( Clinical Trial A ) . Plus , 12 week viral kinetic substudy compare subgroup patient Clinical Trial A conduct . ( Substudy A1 )</brief_summary>
	<brief_title>Virological Clinical Anti-Hepatitis B Virus ( HBV ) Efficacy Tenofovir Emtricitabine Patients With HIV/HBV co-Infection</brief_title>
	<detailed_description>This randomize multicentre trial FTC v TDF/FTC antiretroviral naive subject HIV/HBV co-infection 48 week ( Clinical Trial A ) . Plus , 12 week viral kinetic substudy compare subgroup patient Clinical Trial A conduct . ( Substudy A1 ) Primary Objectives : - To compare proportion subject HBV DNA level limit detection ( &lt; 400 copies/ml ) week 48 treatment group Secondary Objectives : - To evaluate emergence HBV resistance 48 week - To compare proportion patient undetectable HBV DNA week 12 24 treatment group - To compare proportion patient achieve HBeAg HBsAg seroconversion week 12 , 24 48 study - To compare change ALT baseline rate hepatic cytolysis ( ALT &gt; 5x ULN ) - To compare suppression HIV-1 RNA change CD4/CD8 count 48 week - To compare effect therapy histological change liver presence ccc-DNA Enrollment : - 24 patient Clinical trial A ( 16 enter substudy A1 ) . Clinical Trial A : - Patients HIV/HBV co-infection naive HIV/HBV therapy , detectable HBV viraemia willing start antiretroviral therapy . Inclusion Criteria : - Written inform consent - Documented HIV infection - Age 18 – 70 year - HBV DNA &gt; 106 copies/ml Randomization : - Arm 1 : Zidovudine ( AZT ) , emtricitabine ( FTC ) , efavirenz ( EFV ) - Arm 2 : Tenofovir ( TDF ) , emtricitabine ( FTC ) , efavirenz ( EFV )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Written inform consent Documented HIV infection Age 18 – 70 year HBV DNA &gt; 10E6 copies/ml ALT &lt; 10 x ULN ( upper limit normal ) Creatinine &lt; = 2.0mg/dl Platelet count &gt; = 50,000/mm3 HIV1 therapy naive No prior exposure antiHBV agent Hepatitis C viral RNA ( CVRNA ) positive Antihepatitis A virus immunoglobulin M ( HAV IgM ) positive Acute hepatitis ( serum ALT &gt; 1000 U/L ) Prior LAM , TDF , adefovir dipivoxil ( ADV ) therapy Active opportunistic infection Pregnancy lactation Other chronic liver disease Concurrent malignancy require cytotoxic chemotherapy Decompensated Child ’ C cirrhosis Alfafetoprotein ( AFP ) &gt; 3X ULN ( unless negative compute tomography [ CT ] scan magnetic resonance image [ MRI ] within 3 month entry date )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HBV</keyword>
	<keyword>treatment</keyword>
	<keyword>tenofovir</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>Hepatitis B virus infection</keyword>
</DOC>